company background image
NMTC

NeuroOne Medical Technologies NasdaqCM:NMTC Stock Report

Last Price

US$1.72

Market Cap

US$27.9m

7D

-13.6%

1Y

-56.5%

Updated

28 Sep, 2022

Data

Company Financials +
NMTC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NMTC Stock Overview

NeuroOne Medical Technologies Corporation operates as a medical technology company.

NeuroOne Medical Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeuroOne Medical Technologies
Historical stock prices
Current Share PriceUS$1.72
52 Week HighUS$4.25
52 Week LowUS$0.51
Beta0.53
1 Month Change-12.69%
3 Month Change109.53%
1 Year Change-56.46%
3 Year Change-71.33%
5 Year Change-83.62%
Change since IPO-85.67%

Recent News & Updates

Sep 15
We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Aug 03

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

NeuroOne Medical Technologies (NASDAQ:NMTC) entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet (NYSE:ZBH) providing the company with a $3.5M accelerated payment within 10 business days which relates to certain milestone payments. Zimmer Biomet will receive a warrant to purchase 350K shares with an exercise price of $3/share. Under the Exclusive Development and Distribution Agreement signed by both parties in July 2020, Zimmer Biomet has exclusive global distribution rights to distribute the company's Cortical and sEEG diagnostic electrode technology. "This agreement accomplishes multiple objectives for NeuroOne, most importantly by providing additional capital to our balance sheet in the short-term without the need for a highly dilutive financing, and further reinforcing our ongoing partnership with Zimmer," CEO Dave Rosa commented.

Shareholder Returns

NMTCUS Medical EquipmentUS Market
7D-13.6%-2.2%-2.0%
1Y-56.5%-30.1%-20.3%

Return vs Industry: NMTC underperformed the US Medical Equipment industry which returned -31.4% over the past year.

Return vs Market: NMTC underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is NMTC's price volatile compared to industry and market?
NMTC volatility
NMTC Average Weekly Movement19.2%
Medical Equipment Industry Average Movement8.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: NMTC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: NMTC's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a11Dave Rosahttps://n1mtc.com

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne’s combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode.

NeuroOne Medical Technologies Fundamentals Summary

How do NeuroOne Medical Technologies's earnings and revenue compare to its market cap?
NMTC fundamental statistics
Market CapUS$27.88m
Earnings (TTM)-US$11.27m
Revenue (TTM)US$162.07k

172.2x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NMTC income statement (TTM)
RevenueUS$162.07k
Cost of RevenueUS$4.48m
Gross Profit-US$4.32m
Other ExpensesUS$6.95m
Earnings-US$11.27m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.70
Gross Margin-2,664.76%
Net Profit Margin-6,953.03%
Debt/Equity Ratio0%

How did NMTC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NMTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NMTC?

Other financial metrics that can be useful for relative valuation.

NMTC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue110.7x
Enterprise Value/EBITDA-1.6x
PEG Ration/a

Price to Book Ratio vs Peers

How does NMTC's PB Ratio compare to its peers?

NMTC PB Ratio vs Peers
The above table shows the PB ratio for NMTC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.9x
PEYE Precision Optics Corporation
3.8xn/aUS$34.0m
VAPO Vapotherm
3.2x41.5%US$44.6m
ECOR electroCore
1.1x29.4%US$31.2m
AWH Aspira Women's Health
3.4x4.3%US$48.5m
NMTC NeuroOne Medical Technologies
2.6x-7.4%US$27.9m

Price-To-Book vs Peers: NMTC is good value based on its Price-To-Book Ratio (2.6x) compared to the peer average (2.9x).


Price to Earnings Ratio vs Industry

How does NMTC's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Book vs Industry: NMTC is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Medical Equipment industry average (2.4x)


Price to Book Ratio vs Fair Ratio

What is NMTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NMTC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NMTC's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NMTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NMTC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NMTC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is NeuroOne Medical Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-7.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NMTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NMTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NMTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NMTC's revenue (87.6% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: NMTC's revenue (87.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NMTC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has NeuroOne Medical Technologies performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-17.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NMTC is currently unprofitable.

Growing Profit Margin: NMTC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NMTC is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.

Accelerating Growth: Unable to compare NMTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NMTC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).


Return on Equity

High ROE: NMTC has a negative Return on Equity (-106.12%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is NeuroOne Medical Technologies's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NMTC's short term assets ($10.9M) exceed its short term liabilities ($814.5K).

Long Term Liabilities: NMTC's short term assets ($10.9M) exceed its long term liabilities ($138.0K).


Debt to Equity History and Analysis

Debt Level: NMTC is debt free.

Reducing Debt: NMTC currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NMTC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NMTC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34% each year


Discover healthy companies

Dividend

What is NeuroOne Medical Technologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

NeuroOne Medical Technologies Dividend Yield vs Market
How does NeuroOne Medical Technologies dividend yield compare to the market?
SegmentDividend Yield
Company (NeuroOne Medical Technologies)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Medical Equipment)1.9%
Analyst forecast in 3 Years (NeuroOne Medical Technologies)n/a

Notable Dividend: Unable to evaluate NMTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NMTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NMTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NMTC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NMTC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Dave Rosa (58 yo)

5.17yrs

Tenure

US$1,889,351

Compensation

Mr. David A. Rosa, also known as Dave, M.D., serves as an Independent Director of BioRestorative Therapies, Inc. since November 4, 2021. He serves as Member of Advisory Board at NeuroDiagnostics, Inc. Mr....


CEO Compensation Analysis

Dave Rosa's Compensation vs NeuroOne Medical Technologies Earnings
How has Dave Rosa's remuneration changed compared to NeuroOne Medical Technologies's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021n/an/a

-US$11m

Sep 30 2021US$2mUS$411k

-US$10m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020n/an/a

-US$11m

Sep 30 2020US$1mUS$404k

-US$14m

Jun 30 2020n/an/a

-US$14m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019n/an/a

-US$10m

Sep 30 2019US$558kUS$392k

-US$7m

Jun 30 2019n/an/a

-US$8m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018n/an/a

-US$6m

Sep 30 2018US$417kUS$288k

-US$7m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$6m

Dec 31 2017US$496kUS$357k

-US$5m

Sep 30 2017n/an/a

-US$4m

Mar 31 2017n/an/a

-US$990k

Dec 31 2016US$78kUS$75k

-US$266k

Compensation vs Market: Dave's total compensation ($USD1.89M) is above average for companies of similar size in the US market ($USD784.47K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NMTC's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: NMTC's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:NMTC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Jun 22BuyUS$10,219Ronald McClurgIndividual10,000US$1.02
10 Jun 22BuyUS$14,781Ronald McClurgIndividual14,000US$1.06
24 May 22BuyUS$25,215Ronald McClurgIndividual28,000US$0.98

Ownership Breakdown

What is the ownership structure of NMTC?
Owner TypeNumber of SharesOwnership Percentage
Institutions416,8922.6%
Individual Insiders1,004,8576.2%
Hedge Funds2,863,33217.7%
General Public11,924,15173.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.1%.


Top Shareholders

Top 20 shareholders own 26.44% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.25%
Manchester Management Company, LLC
1,500,001$2.6m0%8.44%
8.41%
AWM Investment Company Inc
1,363,331$2.3m-3.6%0.4%
2.17%
Mark Christianson
351,169$604.0k0%no data
1.68%
David Rosa
272,525$468.7k2.99%no data
1.48%
The Vanguard Group, Inc.
239,391$411.8k0%no data
1.01%
James Besser
164,317$282.6k0%no data
0.51%
Morgan Frank
83,334$143.3k0%no data
0.33%
Kingsbury Capital Investment Advisors LLC
53,403$91.9k0%0.14%
0.32%
Ronald McClurg
52,000$89.4k0%no data
0.31%
Intersect Capital LLC
50,000$86.0k0%0.03%
0.3%
Geode Capital Management, LLC
48,716$83.8k30.8%no data
0.22%
Jeffrey Mathiesen
36,437$62.7k5.55%no data
0.19%
Paul Buckman
31,049$53.4k6.57%no data
0.095%
Northern Trust Global Investments
15,376$26.4k0%no data
0.087%
Edward Andrle
14,026$24.1k15.81%no data
0.033%
Tower Research Capital LLC
5,405$9.3k0%no data
0.021%
Theta 1 Investments & Securities Ltd
3,333$5.7k0%1.56%
0.0054%
UBS Asset Management
881$1.5k0%no data
0.0019%
Cutler Group LP, Asset Management Arm
300$516.00%no data
0.00054%
Wells Fargo & Company, Private Banking and Investment Banking Arm
87$149.68.75%no data

Company Information

NeuroOne Medical Technologies Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: NeuroOne Medical Technologies Corporation
  • Ticker: NMTC
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$27.880m
  • Shares outstanding: 16.21m
  • Website: https://n1mtc.com

Number of Employees


Location

  • NeuroOne Medical Technologies Corporation
  • 7599 Anagram Drive
  • Eden Prairie
  • Minnesota
  • 55344
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NMTCNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2021/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.